Stabilized formulations of peptides and proteins protecting against non-enzymatic degradation
Stabilization of water-containing solutions or lyophilizates of proteins and peptide against non-enzymatic deamidation degradation reactions at asparaginyl or glutaminyl residues is achieved using organic anions, such as saccharin, benzenesulfonic acid, gentisic acid or N-acetyltryptophan which have a pKa within the range of 0.5 to 3.5.
1. A peptide or protein composition, comprising:
a. at least one peptide or protein which contains one or more asparaginyl or glutaminyl residues with at least one deamidation prone sequence of -Asn-Gly- protected against non-enzymatic deamidation at at least said deamidation prone sequence, where the peptides or proteins are present in aqueous formulations or lyophilizates; and
b. one or more stabilizing anions to form a mixture wherein said stabilizing anions are present in a molar excess to the total number of asparaginyl or glutaminyl residues in said peptides or proteins and are in a molar excess to any destabilizing anions in said mixture, wherein said stabilizing anions are organic compounds that are not zwitterionic where each protic group of said stabilizing anion has a pKa ranging from 0.5 to 3.5, wherein destabilizing anions have at least one protic group that has a pKa of less than 0.5 or greater than 3.5, and wherein said stabilizing anions are selected from the group consisting of saccharin, benzenesulfonic acid, gentisic acid, and N-acetyltryptophan;
wherein said mixture includes at least one destabilizing anion and said stabilizing anions are present at a molar excess of at least 3:1 relative to said at least one destabilizing anion.
2. The peptide or protein composition of claim 1 ,
wherein an aqueous formulation of said peptide or protein composition comprises a pharmaceutically-acceptable preparation suitable for administration to a human or other mammal by a parenteral route selected from the group consisting of infusion, injection, inhalation, ophthalmic administration, and depot administration, and
wherein a lyophilizate of said peptide or protein composition is suitable for reconstitution as a pharmaceutically-acceptable preparation suitable for administration to a human or other mammal by a parenteral route selected from the group consisting of infusion, injection, inhalation, ophthalmic administration, and depot administration.
3. The peptide or protein composition of claim 2 , wherein said pharmaceutically acceptable preparation is formulated for infusion or injection of a type selected from the group consisting of intravenous, intraperitoneal, intrathecal, intramuscular, subcutaneous, intra-arterial, intravaginal, intraocular, intranasal, opthalmic, epidural, intracisternal, and intrathoracic.
4. The peptide or protein composition of claim 2 , wherein said pharmaceutically acceptable preparation is formulated for ophthalmic administration by a route selected from the group consisting of periocular, intraocular, conjunctival, subconjunctival, transconjunctival, peribulbar, retrobulbar, subtenons, transscleral, intraorbital, intrascleral, intravitreal, subretinal, transretinal, choroidal, uveal, intracameral, intracorneal, intralenticular, and in or adjacent to the optic nerve.
5. The peptide or protein composition of claim 2 , wherein said pharmaceutically acceptable preparation is formulated for depot administration by a route selected from the group consisting of otic, intranasal, intracisternal, intramuscular, intravaginal and bladder instillation.